Cerecor Inc. (Nasdaq: CERC) reported disappointing results from Phase 2 clinical trial of CERC-501 sending the stock price down 23 cents to close at $1.52.
Cerecor disappoints
December 05, 2016 at 16:52 PM EST
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.